Acorn Capital Advisors as of March 31, 2025
Portfolio Holdings for Acorn Capital Advisors
Acorn Capital Advisors holds 22 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Cg Oncology (CGON) | 19.3 | $28M | 1.1M | 24.50 | |
| Urogen Pharma (URGN) | 11.7 | $17M | 1.5M | 11.06 | |
| Y Mabs Therapeutics (YMAB) | 10.0 | $14M | 3.2M | 4.43 | |
| Trevi Therapeutics (TRVI) | 9.4 | $14M | 2.1M | 6.29 | |
| Candel Therapeutics (CADL) | 8.5 | $12M | 2.2M | 5.65 | |
| Puma Biotechnology (PBYI) | 8.1 | $12M | 3.9M | 2.96 | |
| Bicara Therapeutics (BCAX) | 5.8 | $8.4M | 643k | 13.03 | |
| Protara Therapeutics Com Stk (TARA) | 3.8 | $5.5M | 1.3M | 4.26 | |
| Terns Pharmaceuticals (TERN) | 3.8 | $5.4M | 2.0M | 2.76 | |
| Cybin Com New (CYBN) | 3.2 | $4.7M | 734k | 6.35 | |
| Cardiff Oncology (CRDF) | 3.2 | $4.5M | 1.4M | 3.14 | |
| Optinose Com New | 2.7 | $3.9M | 423k | 9.17 | |
| Verastem (VSTM) | 1.9 | $2.7M | 452k | 6.03 | |
| Aadi Bioscience (WHWK) | 1.4 | $2.0M | 1.1M | 1.78 | |
| X4 Pharmaceuticals | 1.2 | $1.8M | 7.3M | 0.24 | |
| Mural Oncology (MURA) | 1.1 | $1.6M | 1.3M | 1.26 | |
| Aura Biosciences (AURA) | 1.0 | $1.5M | 591k | 2.46 | |
| Bioatla (BCAB) | 1.0 | $1.4M | 4.0M | 0.35 | |
| Q32 Bio (QTTB) | 0.9 | $1.3M | 803k | 1.65 | |
| Vyne Therapeutics (VYNE) | 0.9 | $1.2M | 786k | 1.58 | |
| Onkure Therapeutics Class A Com (OKUR) | 0.6 | $857k | 199k | 4.30 | |
| Acrivon Therapeutics Common Stock (ACRV) | 0.6 | $823k | 405k | 2.03 |
